Belvedere Trading LLC Invests $3.48 Million in VanEck Pharmaceutical ETF $PPH

Belvedere Trading LLC acquired a new position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 33,767 shares of the company’s stock, valued at approximately $3,484,000. VanEck Pharmaceutical ETF comprises 0.0% of Belvedere Trading LLC’s portfolio, making the stock its 24th largest position.

A number of other institutional investors also recently made changes to their positions in PPH. Citigroup Inc. boosted its holdings in shares of VanEck Pharmaceutical ETF by 987.8% during the third quarter. Citigroup Inc. now owns 718,199 shares of the company’s stock worth $64,896,000 after acquiring an additional 652,175 shares during the period. Revere Asset Management Inc bought a new stake in shares of VanEck Pharmaceutical ETF during the third quarter worth approximately $15,628,000. UBS Group AG boosted its holdings in shares of VanEck Pharmaceutical ETF by 145.8% during the fourth quarter. UBS Group AG now owns 107,379 shares of the company’s stock worth $11,078,000 after acquiring an additional 63,692 shares during the period. Qube Research & Technologies Ltd raised its position in shares of VanEck Pharmaceutical ETF by 368.5% in the third quarter. Qube Research & Technologies Ltd now owns 75,844 shares of the company’s stock valued at $6,853,000 after buying an additional 59,654 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of VanEck Pharmaceutical ETF by 346,140.0% in the second quarter. Tower Research Capital LLC TRC now owns 34,624 shares of the company’s stock valued at $3,046,000 after buying an additional 34,614 shares in the last quarter.

Get VanEck Pharmaceutical ETF alerts:

VanEck Pharmaceutical ETF Trading Down 0.9%

NASDAQ PPH opened at $104.74 on Friday. VanEck Pharmaceutical ETF has a 1-year low of $81.74 and a 1-year high of $112.58. The company has a 50 day moving average of $102.50 and a 200-day moving average of $103.94. The company has a market cap of $993.98 million, a price-to-earnings ratio of 20.21 and a beta of 0.46.

VanEck Pharmaceutical ETF Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Wednesday, April 1st were given a $0.8441 dividend. The ex-dividend date was Wednesday, April 1st. This is a positive change from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.31. This represents a $3.38 dividend on an annualized basis and a dividend yield of 3.2%.

VanEck Pharmaceutical ETF Profile

(Free Report)

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.

Featured Stories

• Five stocks we like better than VanEck Pharmaceutical ETF
• Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
• Salesforce Stock Finds Support as AI Momentum Builds
• Dollar Tree Keeps Winning After Family Dollar Divorce
• Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet

Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).

Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.